Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2019
August 19, 2019 at 04:26 pm EDT
Share
Regenicin, Inc. announced earnings results for the third quarter ended June 30, 2019. For the third quarter, the company announced operating loss was USD 176,234 compared to USD 181,937 a year ago. Net loss was USD 182,871 compared to USD 186,388 a year ago. For the nine months, operating loss was USD 591,387 compared to USD 613,389 a year ago. Net loss was USD 608,528 compared to USD 627,760 a year ago.
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.
REGENICIN, INC. 
